Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis)

Abrocitinib, an oral selective Janus kinase 1 inhibitor, is approved for the treatment of moderate-tosevere atopic dermatitis (AD) in adults, but realworld evidence remains limited. We retrospectively collected data from 187 adult patients (mean age:37.9 years; 60.4% male), with AD and up to oneyear exposure to abrocitinib either 100 or 200 mg, between 2023 and 2025 across 22 Italian dermatology centres. Nearly half of patients were bio-experienced and 80 % had difficult-to-treat areas. Beginning at week 8, with either 100 (59%) or 200 mg, 52 % achieved Investigator Global Assessment 0/1, significantly increasing to 88 % at week 52. Similarly, Eczema Area and Severity Index (EASI) and itch had significantly higher 1-year response: increasing from 27.8% and 34.7%, respectively, at week 8, 79.6 % achieved EASI-90 and 73.5% reached Peak Pruritus-Numerical Rating Scale 0/1. Minimal disease activity, a stringent composite endpoint, was met by 18 % at week 8 and by 66 % at week 52. Safety was good, with mild adverse events mostly including abdominal pain, upper respiratory infections and headache. The 100 mg dose had a significantly better safety profile, with efficacy similar to 200 mg. These data confirm the efficacy and safety of abrocitinib, with early, progressive clinical benefits sustained through 1 year.

Authors

Institutions

Publication Details

Journal
Acta Dermato Venereologica
Published
2026-04-14
DOI
https://doi.org/10.2340/actadv.v106.adv-2025-0193
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis)

Martina Maurelli, Simone Ribero, Maddalena Napolitano, Maria Esposito et al.
Acta Dermato Venereologica
Dermatology and Skin Diseases
article

Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis)

Martina Maurelli, Simone Ribero, Maddalena Napolitano, Maria Esposito, Giampiero Girolomoni, Carlotta Gurioli, Paola Savoia, Antonio Costanzo, Anna Balato, Maria Concetta Fargnoli, Fabrizio M. Amoruso, Piergiacomo Calzavara‐Pinton, Michela Ortoncelli, Elena Pezzolo, Cataldo Patruno, A. Burroni, Flavia Manzo Margiotta, Claudio Sciarrone, Francesca Satolli, Federica Veronese, Marco Romanelli, Alessandra Narcisi, Cristina Beatrice Spigariolo, Francesca Barei, Benedetta Tirone, Rossi Mariateresa, Maria L. Musumeci, Luigi Naldi, Marco Vaccino, Luigi Gargiulo, Silvia M. Ferrucci, Caterina Foti, Massimo Gola, Piergiorgio Malagoli, Raul Armando Luyo Saboya
article en

Abstract

Abrocitinib, an oral selective Janus kinase 1 inhibitor, is approved for the treatment of moderate-tosevere atopic dermatitis (AD) in adults, but realworld evidence remains limited. We retrospectively collected data from 187 adult patients (mean age:37.9 years; 60.4% male), with AD and up to oneyear exposure to abrocitinib either 100 or 200 mg, between 2023 and 2025 across 22 Italian dermatology centres. Nearly half of patients were bio-experienced and 80 % had difficult-to-treat areas. Beginning at week 8, with either 100 (59%) or 200 mg, 52 % achieved Investigator Global Assessment 0/1, significantly increasing to 88 % at week 52. Similarly, Eczema Area and Severity Index (EASI) and itch had significantly higher 1-year response: increasing from 27.8% and 34.7%, respectively, at week 8, 79.6 % achieved EASI-90 and 73.5% reached Peak Pruritus-Numerical Rating Scale 0/1. Minimal disease activity, a stringent composite endpoint, was met by 18 % at week 8 and by 66 % at week 52. Safety was good, with mild adverse events mostly including abdominal pain, upper respiratory infections and headache. The 100 mg dose had a significantly better safety profile, with efficacy similar to 200 mg. These data confirm the efficacy and safety of abrocitinib, with early, progressive clinical benefits sustained through 1 year.

Acta Dermato VenereologicaVol. 106
University of Pisa (IT), University of Verona (IT), Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT), University of Parma (IT), Humanitas University (IT), Scuola Superiore Sant'Anna (IT), University of Milan (IT), University of Campania "Luigi Vanvitelli" (IT), University of L'Aquila (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Magna Graecia University (IT), University of Catania (IT), IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT), IRCCS Policlinico San Donato (IT), Azienda Ospedaliera di Cosenza (IT), Azienda Ospedaliero Universitaria Maggiore della Carita (IT), Azienda Ospedaliera Ospedale Maggiore (IT), Ospedale Policlinico San Martino (IT), Ospedale San Bortolo (IT), IRCCS Humanitas Research Hospital (IT), University of Florence (IT), University of Turin (IT), University of Bari Aldo Moro (IT), University of Naples Federico II (IT), University of Brescia (IT)
Good health and well-being
Openalex Percentile: Top 21%
Dermatology and Skin Diseases
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.